Lower Prices, Bigger Market: The Next Phase of GLP-1 Drugs

The emergence of lower-cost semaglutide generics in markets like India, Canada, and Brazil provides a critical blueprint for future pharmaceutical trends in the U.S. and Europe. While generic entry drives significant volume expansion—evidenced by a sixfold increase in India following launch—the market is increasingly segmenting. High-efficacy, dual-pathway drugs like tirzepatide maintain a competitive edge, commanding a premium despite the availability of cheaper alternatives. Supply chain stability remains robust for active pharmaceutical ingredients and devices, though fill-and-finish capacity poses a potential bottleneck due to long lead times for clean-room infrastructure. Looking ahead, the "diabesity" market will be shaped by the introduction of oral formulations, continued innovation in longer-acting injectables, and expanded patient access through programs like Medicare, which will soon provide coverage for millions of U.S. seniors.